geoffrey modest medical blogs

  A post hoc analysis of the Look AHEAD study, which involved extensive nonpharmacologic therapies for those with diabetes, found that individuals achieving diabetes remission had significantly decreased incidence of chronic kidney disease (CKD) and cardiovascular disease (CVD): see  dm remission dec CKD CVD Diab2024  in dropbox, or  doi.org/10.1007/s00125-023-06048-6 Background information on the Look AHEAD study: -- the Look AHEAD study is a multicenter RCT assessing the effect of a 12 year intensive lifestyle intervention in individuals with diabetes, finding that diabetes remission occurred in 12% of all intervention participants and also that 21% of those with fewer than two years of diabetes duration achieved remission the first year and 10% achieved two years of remission (remission was assessed annually) -- the Look AHEAD study,  a multicenter RCT assessing the effect of a 12 year intensive lifestyle intervention in individuals with diabetes , compared  intensive lifestyle inte

  An updated study assessed the longer-term effects of the  medication tirzepatide  on weight reduction, comparing those who continued the tirzepatide versus those who stopped it, in the SURMOUNT4 trial (see  obesity tirzepatide discont and inc wt JAMA 2024  in dropbox, or  doi:10.1001/jama.2023.24945 )   Details : -- this is a phase 3, randomized withdrawal clinical trial in 70 sites in 4 countries (Argentina, Brazil, Taiwan and the US) from 2021 to 2023, with two phases:     -- all patients took open-label tirzepatide weekly to their maximum tolerated dose, in this lead-in period lasting until week 36         -- initiation for tirzepatide therapy was by the standard approach: 2.5 mg weekly initially with an increase of 2.5 mg every four weeks until the maximum tolerated dose of up to 15 mg     -- 670 patients at week 36 were then randomized to continuing to receive tirzepatide versus a switch to placebo, with follow-up for 52 more weeks; this part of the study included only those pat